Well that's not what was said at all. I said that since MSB had defined HF-MACE after they knew the results, if there was some benefit you would expect to see it in other surrogates.
- Remember the Pseudo Scientists (shorters) saying again and again how MACE was irrelevant and the only thing that mattered was ejection fraction.
Novartis at least defined MACE in a standard way rather than throwing out heart bypasses and non-fatal heart attack because the product candidate had exactly the same number of MACE as the control group, despite being more healthy to start with, like in MSB's phase II trial.
Just be warned, if those results are repeated, then we might find that
HF-MACE P3 [ PART 4 ], page-3
-
- There are more pages in this discussion • 16 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
94.5¢ |
Change
-0.025(2.58%) |
Mkt cap ! $1.078B | |||
| Open | High | Low | Value | Volume |
| 98.0¢ | 98.5¢ | 94.0¢ | $2.482M | 2.602M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 71720 | 94.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 94.5¢ | 10463 | 1 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| MSB (ASX) Chart |